Eli Lilly’s oral obesity drug Foundayo (orforglipron) won FDA authorization, but the initial market reaction cooled quickly as investors weighed sales ramp and pricing pressure. Shares rose the day of the decision, then reversed into a loss, reflecting uncertainty around how fast the pill formulation can convert into meaningful prescription volume. Analysts cited pricing dynamics against obesity arch-rival Novo Nordisk, which already holds FDA approval for an oral semaglutide product. The competitive landscape is further shaped by dosing logistics and distribution through Lilly’s direct-to-consumer platform, with a range of monthly price points outlined for different dose strengths. While manufacturing costs may be lower for a tablet versus capsule-based formulations studied in trials, the near-term question for investors is how pricing and payer coverage will translate into net sales during the first full year on the market.